DOCSLIB.ORG

Product List Clinical

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Product List Clinical APRIL 2017 PRODUCT LIST CLINICAL 1 MANUAL BLOOD CULTURE / IDENTIFICATION & SEROLOGY / RAPID MOLECULAR ENVIRONMENTAL HOME HOW TO USE MYCOBACTERIAL LAB EFFICIENCY CULTURE MEDIA IMMUNOASSAYS INDEX SUSCEPTIBILITY TEST / BIOLOGY MONITORING CULTURE IMMUNOLOGY HOME BIOMÉRIEUX: INNOVATIVE DIAGNOSTIC SOLUTIONS SALES ORDERS & ENQUIRIES DELIVERY CUSTOMER SERVICE SUPPORT TRAINING AND EDUCATION TECHNICAL LIBRARY & QUALITY CONTROL CERTIFICATE BIOMÉRIEUX AN INSTITUT MÉRIEUX COMPANY PRODUCT QUALITY AND SAFETY CORPORATE RESPONSIBILITY GENERAL CONDITIONS OF SALE LEGAL HOW TO USE BLOOD CULTURE / MYCOBACTERIAL CULTURE LAB EFFICIENCY CULTURE MEDIA IDENTIFICATION & SUSCEPTIBILITY IMMUNOASSAYS MANUAL SEROLOGY / RAPID TEST / IMMUNOLOGY HOME MOLECULAR BIOLOGY ENVIRONMENTAL MONITORING bioMérieux UK +44 (0)1256 480701 +44 (0)1256 816863 [email protected] www.biomerieux.co.uk 2 PRODUCT LIST CLINICAL APRIL 2017 MANUAL BLOOD CULTURE / IDENTIFICATION & SEROLOGY / RAPID MOLECULAR ENVIRONMENTAL HOME HOW TO USE MYCOBACTERIAL LAB EFFICIENCY CULTURE MEDIA IMMUNOASSAYS INDEX SUSCEPTIBILITY TEST / BIOLOGY MONITORING CULTURE IMMUNOLOGY BIOMÉRIEUX: INNOVATIVE DIAGNOSTIC SOLUTIONS SALES ORDERS & ENQUIRIES DELIVERY CUSTOMER SERVICE SUPPORT TRAINING AND EDUCATION TECHNICAL LIBRARY & QUALITY CONTROL BIOMÉRIEUX: INNOVATIVE CERTIFICATE BIOMÉRIEUX AN INSTITUT MÉRIEUX COMPANY PRODUCT QUALITY AND SAFETY DIAGNOSTIC SOLUTIONS CORPORATE RESPONSIBILITY GENERAL CONDITIONS OF SALE LEGAL of in vitro diagnostics for over 50 years, bioMérieux is present in more than 150 countries through 42 subsidiaries and a large network of distributors. in itro 3 PRODUCT LIST CLINICAL APRIL 2017 MANUAL BLOOD CULTURE / IDENTIFICATION & SEROLOGY / RAPID MOLECULAR ENVIRONMENTAL HOME HOW TO USE MYCOBACTERIAL LAB EFFICIENCY CULTURE MEDIA IMMUNOASSAYS INDEX SUSCEPTIBILITY TEST / BIOLOGY MONITORING CULTURE IMMUNOLOGY BIOMÉRIEUX: INNOVATIVE DIAGNOSTIC SOLUTIONS SALES ORDERS & ENQUIRIES DELIVERY CUSTOMER SERVICE SUPPORT TRAINING AND EDUCATION SALES ORDERS & ENQUIRIES TECHNICAL LIBRARY & QUALITY CONTROL CERTIFICATE BIOMÉRIEUX AN INSTITUT MÉRIEUX COMPANY r o our commime o cuomer erice we eeour o ec orer receie PRODUCT QUALITY AND SAFETY by oo exce oiy ccori o e eiery be o e . orer re CORPORATE RESPONSIBILITY ubec o ibiiy rom oc. GENERAL CONDITIONS OF SALE LEGAL Sales Orders Quotations Order Enquiries General Enquiries 4 PRODUCT LIST CLINICAL APRIL 2017 MANUAL BLOOD CULTURE / IDENTIFICATION & SEROLOGY / RAPID MOLECULAR ENVIRONMENTAL HOME HOW TO USE MYCOBACTERIAL LAB EFFICIENCY CULTURE MEDIA IMMUNOASSAYS INDEX SUSCEPTIBILITY TEST / BIOLOGY MONITORING CULTURE IMMUNOLOGY BIOMÉRIEUX: INNOVATIVE DIAGNOSTIC SOLUTIONS SALES ORDERS & ENQUIRIES DELIVERY CUSTOMER SERVICE SUPPORT TRAINING AND EDUCATION DELIVERY TECHNICAL LIBRARY & QUALITY CONTROL CERTIFICATE BIOMÉRIEUX AN INSTITUT MÉRIEUX COMPANY orer re ubec o ibiiy rom oc. PRODUCT QUALITY AND SAFETY CORPORATE RESPONSIBILITY rice uoe icue i eiery ubec o miimum orer ue o GENERAL CONDITIONS OF SALE . r cre o . i ie o orer beow i ee. LEGAL you reuire emerecy eiery i c be rre cre e reii re. ree rouc re currey ie irecy o ry ice rom our oc wreoue. ee ow oe wee or eiery. r cre o i me or ee ime. K rders Ireland rders CUSTOMER ORDER DELIVERY – DUBLIN AREA (WITH POSTCODE) DELIVERY – OUTSIDE OF DUBLIN AREA (WITH NO POSTCODE) 5 PRODUCT LIST CLINICAL APRIL 2017 MANUAL BLOOD CULTURE / IDENTIFICATION & SEROLOGY / RAPID MOLECULAR ENVIRONMENTAL HOME HOW TO USE MYCOBACTERIAL LAB EFFICIENCY CULTURE MEDIA IMMUNOASSAYS INDEX SUSCEPTIBILITY TEST / BIOLOGY MONITORING CULTURE IMMUNOLOGY BIOMÉRIEUX: INNOVATIVE DIAGNOSTIC SOLUTIONS SALES ORDERS & ENQUIRIES DELIVERY CUSTOMER SERVICE SUPPORT TRAINING AND EDUCATION CUSTOMER SERVICE SUPPORT TECHNICAL LIBRARY & QUALITY CONTROL CERTIFICATE BIOMÉRIEUX AN INSTITUT MÉRIEUX COMPANY ecic ieeri erice uiry c re oe by our erice uor em. PRODUCT QUALITY AND SAFETY ur eeoe ie re oe oy o riy exce oiy rom .m o .m. CORPORATE RESPONSIBILITY GENERAL CONDITIONS OF SALE Technical Support Engineering Service Support LEGAL • • • • • • air Engineering Service Support Team Technical Support Team General Enquiries 6 PRODUCT LIST CLINICAL APRIL 2017 MANUAL BLOOD CULTURE / IDENTIFICATION & SEROLOGY / RAPID MOLECULAR ENVIRONMENTAL HOME HOW TO USE MYCOBACTERIAL LAB EFFICIENCY CULTURE MEDIA IMMUNOASSAYS INDEX SUSCEPTIBILITY TEST / BIOLOGY MONITORING CULTURE IMMUNOLOGY BIOMÉRIEUX: INNOVATIVE DIAGNOSTIC SOLUTIONS SALES ORDERS & ENQUIRIES DELIVERY CUSTOMER SERVICE SUPPORT TRAINING AND EDUCATION TRAINING AND EDUCATION TECHNICAL LIBRARY & QUALITY CONTROL CERTIFICATE BIOMÉRIEUX AN INSTITUT MÉRIEUX COMPANY Get ready for tomorrow with new knowledge and skills PRODUCT QUALITY AND SAFETY o ee you o e cui ee beer reo o your ee CORPORATE RESPONSIBILITY biorieux i coiuy ui i rii ucio rormme. GENERAL CONDITIONS OF SALE LEGAL • • • • • • • Training Team Telephone: +44 (0)1256 480660 or 01 826 1555 Email: 7 PRODUCT LIST CLINICAL APRIL 2017 MANUAL BLOOD CULTURE / IDENTIFICATION & SEROLOGY / RAPID MOLECULAR ENVIRONMENTAL HOME HOW TO USE MYCOBACTERIAL LAB EFFICIENCY CULTURE MEDIA IMMUNOASSAYS INDEX SUSCEPTIBILITY TEST / BIOLOGY MONITORING CULTURE IMMUNOLOGY BIOMÉRIEUX: INNOVATIVE DIAGNOSTIC SOLUTIONS SALES ORDERS & ENQUIRIES DELIVERY CUSTOMER SERVICE SUPPORT TRAINING AND EDUCATION TECHNICAL LIBRARY & QUALITY CONTROL CERTIFICATE BIOMÉRIEUX AN INSTITUT MÉRIEUX COMPANY cce o our ecic ibrry i rou e biorieux webie ur reoure mei rouc mu be e by our uiy PRODUCT QUALITY AND SAFETY cic o ecic ibrry erc i e rouc me or oro erme ceriice rouce beore ey CORPORATE RESPONSIBILITY reerece umber. ce you e reiere wi re reee or e. e eriice or ee oer GENERAL CONDITIONS OF SALE www.mybiomerieux.com you c cce rouc c be ccee irecy i www.mybiomerieux.com. LEGAL ou c erc or ee ui e rouc me reerece • umber or e o umber. • • piry ates • • • 8 PRODUCT LIST CLINICAL APRIL 2017 MANUAL BLOOD CULTURE / IDENTIFICATION & SEROLOGY / RAPID MOLECULAR ENVIRONMENTAL HOME HOW TO USE MYCOBACTERIAL LAB EFFICIENCY CULTURE MEDIA IMMUNOASSAYS INDEX SUSCEPTIBILITY TEST / BIOLOGY MONITORING CULTURE IMMUNOLOGY BIOMÉRIEUX: INNOVATIVE DIAGNOSTIC SOLUTIONS SALES ORDERS & ENQUIRIES DELIVERY CUSTOMER SERVICE SUPPORT TRAINING AND EDUCATION BIOMERIEUX, AN INSTITUT MÉRIEUX COMPANY TECHNICAL LIBRARY & QUALITY CONTROL CERTIFICATE BIOMÉRIEUX AN INSTITUT MÉRIEUX COMPANY bioMérieux is 59% owned by Institut Mérieux. Within the scope of a global, long-term vision, Institut Mérieux contributes its experience in PRODUCT QUALITY AND SAFETY industrial biology to improving medicine and public health across the globe. To fight against infectious diseases and cancers, the Institute CORPORATE RESPONSIBILITY designs and develops new approaches in the fields of diagnostics, immunotherapy, food safety and nutrition. GENERAL CONDITIONS OF SALE LEGAL Its three bio-industrial companies – bioMérieux, Transgene and Mérieux NutriSciences – working closely with its entities devoted to innovation, including Mérieux Développement and ABL Inc., have contributed to major advances in medicine and public health. Institut Mérieux employs more than 15,000 people around the world. It is present in more than 40 countries. 9 PRODUCT LIST CLINICAL APRIL 2017 MANUAL BLOOD CULTURE / IDENTIFICATION & SEROLOGY / RAPID MOLECULAR ENVIRONMENTAL HOME HOW TO USE MYCOBACTERIAL LAB EFFICIENCY CULTURE MEDIA IMMUNOASSAYS INDEX SUSCEPTIBILITY TEST / BIOLOGY MONITORING CULTURE IMMUNOLOGY BIOMÉRIEUX: INNOVATIVE DIAGNOSTIC SOLUTIONS SALES ORDERS & ENQUIRIES DELIVERY CUSTOMER SERVICE SUPPORT TRAINING AND EDUCATION PRODUCT QUALITY AND SAFETY TECHNICAL LIBRARY & QUALITY CONTROL CERTIFICATE BIOMÉRIEUX AN INSTITUT MÉRIEUX COMPANY PRODUCT QUALITY AND SAFETY Each day, across the globe, CORPORATE RESPONSIBILITY GENERAL CONDITIONS OF SALE the quality of our diagnostic LEGAL tests determines the treatment prescribed by a healthcare professional or the marketing of a food product. In vitro diagnostics plays an essential role in public When it comes to our Quality Policy, we adopt a holistic approach: health: it is our responsibility to help customers do their our goal is to integrate Quality into every aspect of our work. jobs well by understanding their needs and by delivering We have established a Global Quality Management System results that will enable physicians to make treatment to oversee our processes and manage risk. This approach decisions. Our Quality Policy is central to achieving this. helps ensure compliance with regulatory requirements. In New companies, new subsidiaries, new products: the scope addition, it reduces our production cycle times, limits product of our growth and the complexity of our activity in an nonconformities and results in an optimized supply chain to extremely regulated environment require us to move
Load more

Recommended publications
  • Figure 1: Etest Gradient Configuration When an Etest Gradient Strip Is
    Inoculum preparation Table 1. Recommended media, inoculum and To obtain reproducible MICs from a gradient based Use the inoculum guide in TABLE 1. Emulsify several incubation1). system, the stability of the gradient must be maintai- well-isolated colonies from an overnight agar plate in lêÖ~åáëã= ^Ö~ê= fåçÅìäìã fåÅìÄ~íáçå ned throughout the critical period when the position a suitable suspension medium to achieve the specifi ed Öêçìé ãÉÇá~ of the growth/inhibition edge for a particular bac- inoculum turbidity by comparing to a McFarland pìëéÉåëáçå qìêÄáÇáíó= qÉãéÉê~íìêÉ= ^íãçëéÜÉêÉ qáãÉ= Antimicrobial Susceptibility Testing terium/antibiotic combination is determined. Due turbidity standard. For fastidious organisms such as EjÅc~êä~åÇF Eœ=O=ø`F EÜçìêëF For In Vitro Diagnostic Use to the stability and precision of the Etest predefi ned pneumococci, streptococci, gonococci, anaerobes and gradient, MIC values have been shown to be repro- Haemophilus spp., use the suspension prepared in INTENDED USE ducible and equivalent to those of the CLSI reference broth within 15 minutes. ^ÉêçÄÉë jìÉääÉê= MKURB=k~`ä MKR================== PR=ø` ~ãÄáÉåí NSJOM Etest is a quantitative technique for determining dilution procedures. eáåíçå EN=áÑ=ãìÅçáÇF the antimicrobial susceptibility of Gram negative Inoculation and Gram positive aerobic bacteria such as En- REAGENTS Soak a sterile, non-toxic swab in the inoculum terobacteriaceae, Pseudomonas, Staphylococcus and Etest is supplied in a package of 100 or 30 (some suspension and remove excess fl uid by pressing it lop^L=lopb jìÉääÉê= MKURB=k~`ä MKR PR=ø` ~ãÄáÉåí OQ=lop^==== Enterococcus species and fastidious bacteria, such as reagents) test strips of one antimicrobial agent.
    [Show full text]
  • Laboratory Manual for Diagnosis of Sexually Transmitted And
    Department of AIDS Control LaborLaboraattororyy ManualManual fforor DiagnosisDiagnosis ofof SeSexxuallyually TTrransmitansmittteded andand RRepreproductivoductivee TTrractact InInffectionsections FOREWORD Sexually Transmitted Infections (STIs) and Reproductive Tract Infections (RTIs) are diseases of major global concern. About 6% of Indian population is reported to be having STIs. In addition to having high levels of morbidity, they also facilitate transmission of HIV infection. Thus control of STIs goes hand in hand with control of HIV/AIDS. Countrywide strengthening of laboratories by helping them to adopt uniform standardized protocols is very important not only for case detection and treatment, but also to have reliable epidemiological information which will help in evaluation and monitoring of control efforts. It is also essential to have good referral services between primary level of health facilities and higher levels. This manual aims to bring in standard testing practices among laboratories that serve health facilities involved in managing STIs and RTIs. While generic procedures such as staining, microscopy and culture have been dealt with in detail, procedures that employ specific manufacturer defined kits have been left to the laboratories to follow the respective protocols. An introduction to quality system essentials and quality control principles has also been included in the manual to sensitize the readers on the importance of quality assurance and quality management system, which is very much the need of the hour. Manual of Operating Procedures for Diagnosis of STIs/RTIs i PREFACE Sexually Transmitted Infections (STIs) are the most common infectious diseases worldwide, with over 350 million new cases occurring each year, and have far-reaching health, social, and economic consequences.
    [Show full text]
  • Sexually Transmitted Diseases Treatment Guidelines, 2015
    Morbidity and Mortality Weekly Report Recommendations and Reports / Vol. 64 / No. 3 June 5, 2015 Sexually Transmitted Diseases Treatment Guidelines, 2015 U.S. Department of Health and Human Services Centers for Disease Control and Prevention Recommendations and Reports CONTENTS CONTENTS (Continued) Introduction ............................................................................................................1 Gonococcal Infections ...................................................................................... 60 Methods ....................................................................................................................1 Diseases Characterized by Vaginal Discharge .......................................... 69 Clinical Prevention Guidance ............................................................................2 Bacterial Vaginosis .......................................................................................... 69 Special Populations ..............................................................................................9 Trichomoniasis ................................................................................................. 72 Emerging Issues .................................................................................................. 17 Vulvovaginal Candidiasis ............................................................................. 75 Hepatitis C ......................................................................................................... 17 Pelvic Inflammatory
    [Show full text]
  • Comparison of the Etest and the Routine Multi-Disc Agar Diffusion Susceptibility of Staphylococcus Species
    Yah SC Etest and routine agar testing of Staphylococcus Comparison of the Etest and the routine multi-disc agar diffusion susceptibility of Staphylococcus species *Yah SC1, Ching FP2 and Atuanya EI3 Abstract. Aims: The present study, tend to evaluate the validity and accuracy of Etest as a method for performing in-vitro antimicrobial susceptibility testing of Staphylococcus with comparison to the routine multi disc agar diffusion. This is because the Etest susceptibility method is not yet known as a rapid, simple reliable technique in developing countries as it combine the functions of both dilution and diffusion technique. Materials and methods: Ninety-seven Staphylococcus aureus and eighty- three Staphylococcus epidermidis isolates were obtained from wound samples and identified according to standard morphological and biochemical methods. The antibiotics susceptibility patterns were determined both by agar disc diffusion and Etest methods in accordance to NCCLS (1997) criteria and manufacturer (AB Biodisk Sweden) respectively. Results: On the Etest strips, Staph aureus was 83.5% sensitive to ciprofloxacin, 52.6% to gentamicin, 48.5% to ampicillin and 8.2% to chloramphenicol while on the multi-disc agar diffusion plates 80.4% of Staph aureus were sensitive to ciprofloxacin, 49.5% to gentamicin, 39.2% to ampicillin and 12.4% to chloramphenicol.. On the Etest strips, 80.7% of Staph epidermidis were sensitive to ciprofloxacin, 34.9% to gentamicin, 25.3% to ampicillin and 15.7% to chloramphenicol while on the multi- disc agar diffusion plates 89.2% of Staph epidermidis were sensitive to ciprofloxacin, 34.9% to gentamicin, 25.3% to ampicillin and 32.5% to chloramphenicol.
    [Show full text]
  • Biomerieux Product List 2016
    HOW BLOOD CULTURE / FULL MICROBIOLOGY IDENTIFICATION & MANUAL SEROLOGY / MOLECULAR ENVIRONMENTAL SHORT HOME TO USE MYCOBACTERIAL CULTURE LABLAB AUTOMATION CULTURE MEDIA SUSCEPTIBILITY AND QC IMMUNOASSAYS RAPID TEST / IMMUNOLOGY BIOLOGY MONITORING CUTS CLINIC AL PRODUC T LIST JANUARY 2016 1 www.biomerieux-nordic.com HOW BLOOD CULTURE / FULL MICROBIOLOGY IDENTIFICATION & MANUAL SEROLOGY / MOLECULAR ENVIRONMENTAL SHORT HOME TO USE MYCOBACTERIAL CULTURE LABLAB AUTOMATION CULTURE MEDIA SUSCEPTIBILITY AND QC IMMUNOASSAYS RAPID TEST / IMMUNOLOGY BIOLOGY MONITORING CUTS HOME Our Principles Sales Orders & Enquiries Customer Support Training and Education Technical Library & Quality Control Certificates History bioMérieux Quality bioMérieux Goes Green Terms & Conditions Legal PIONEERING DIAGNOSTICS to improve public health especially in the fight of infectious diseases. 2 www.biomerieux-nordic.com HOW BLOOD CULTURE / FULL MICROBIOLOGY IDENTIFICATION & MANUAL SEROLOGY / MOLECULAR ENVIRONMENTAL SHORT HOME TO USE MYCOBACTERIAL CULTURE LABLAB AUTOMATION CULTURE MEDIA SUSCEPTIBILITY AND QC IMMUNOASSAYS RAPID TEST / IMMUNOLOGY BIOLOGY MONITORING CUTS HOME Our Principles Our Principles Sales Orders & Enquiries Customer Support Customers come First Training and Education We must satisfy our customers Technical Library & Quality Control Certificates – clinicians and laboratory professionals – History bioMérieux with high quality, innovative products and Quality services to protect and improve the health bioMérieux Goes Green of patients and consumers worldwide. Terms & Conditions Legal Employees are our Greatest Asset We must respect and recognise the work and the ideas of all employees, no matter what their job. We work together towards a common goal: satisfy our customers. We must provide employees with the training and resources they need to achieve this. We Belong to a Community We have social, environmental and economic responsibilities towards the local communities where our sites are located.
    [Show full text]
  • Fosfomycin Drug Review
    THE NEBRASKA MEDICAL CENTER FOSFOMYCIN: REVIEW AND USE CRITERIA BACKGROUND Fosfomycin is a phosphonic acid derivative, which inhibits peptidoglycan assembly, thereby disrupting cell wall synthesis.1 Its uptake into the bacterial cell occurs via active transport, by the L-α-glycerophosphate transport and hexose phosphate uptake systems. Once inside the bacteria, it competes with phosphoenolpyruvate to irreversibly inhibit the enzyme enolpyruvyl transferase that catalyzes the first step of peptidoglycan synthesis.1,2 By irreversibly blocking this enzyme, cell wall synthesis is interrupted. Fosfomycin also decreases bacteria adherence to uroepithelial cells. Fosfomycin has been approved by the Food and Drug Administration (FDA) for the treatment of uncomplicated urinary tract infection (UTI) in adult women that is caused by Escherichia coli and Enterococcus faecalis.2 Oral fosfomycin has also been used for non-FDA approved indication such as complicated UTI without bacteremia. Intravenous fosfomycin, which is not available in the US, has also been used for a variety of infections including meningitis, pneumonia, and pyelonephritis.2 Fosfomycin does not have an indication for the treatment of pyelonephritis or perinephric abscess.2,3 Fosfomycin has broad spectrum of activity against aerobic gram positive and gram negative pathogens. It was shown in vitro and in clinical studies, to have activity against ≥90% of strains of E. coli, Citrobacter diversus, C. freundii, Klebsiella oxytoca, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, P. vulgaris, Providencia rettgeri, Pseudomonas aeruginosa, E. faecalis and E. faecium [including vancomycin resistant (VRE)] species, and Staphylococcus aureus [including Methicillin resistant Staphylococcus aureus (MRSA)] associated with UTI.2,3 Currently, the Clinical and Laboratory Standards Institute (CLSI) susceptibility breakpoints exist only for E.
    [Show full text]
  • Laboratory Protocols Level 1 Training Course Agar Diffusion Using E-Test 4
    Global Salm-Surv A global Salmonella surveillance and laboratory support project of the World Health Organization Laboratory Protocols Level 1 Training Course Agar diffusion using E-test 4th Ed. April 2003 EDITED BY: RENE S. HENDRIKSEN (DFVF) Contents Page 1. Susceptibility testing: Determination of phenotypic resistance...........................................3 1.2 Agar diffusion with E-test (determination of an approximate MIC-value).........................5 2. Composition and preparation of culture media and reagents.............................................10 Laboratory record sheets...........................................................................................................11 2 1. Susceptibility testing: Determination of phenotypic resistance 1) Agar diffusion with disk 2) Agar diffusion with E-test 3) MIC-determination using Agar dilution method. Introduction The MIC (Minimal Inhibitory Concentration) of a bacterium to a certain antimicrobial agent gives a quantitative estimate of the susceptibility. MIC is defined as the lowest concentration of antimicrobial agent required to inhibit growth of the organism. The principle is simple: Agar plates, tubes or microtitre trays with two-fold dilutions of antibiotics are inoculated with a standardised inoculum of the bacteria and incubated under standardised conditions following NCCLS guidelines. The next day, the MIC is recorded as the lowest concentration of antimicrobial agent with no visible growth. The MIC informs you about the degree of resistance and might give you important information about the resistance mechanism and the resistance genes involved. MIC-determination performed as agar dilution is regarded as the gold standard for susceptibility testing. Agar diffusion tests are often used as qualitative methods to determine whether a bacterium is resistant, intermediately resistant or susceptible. However, the agar diffusion method can be used for determination of MIC values provided the necessary reference curves for conversion of inhibition zones into MIC values are available.
    [Show full text]
  • The Challenge of Antimicrobial Susceptibility Testing in Iran
    The Challenge of Antimicrobial Susceptibility Testing in Iran Mohammad Rahbar(Ph.D) P Arofessor of Clinical Microbiology Tehran April 23, 2017 Introduction • Antimicrobial resistance is a critical public health and safety dilemma. We have witnessed a seemingly inexorable increase in the number of infections due to carbapenem- resistant Enterobacteriaceae, multidrug- resistant (MDR) Pseudomonas aeruginosa, MDR Acinetobacter baumannii, and vancomycin-resistant Enterococcus faecium. Introduction The performance of antimicrobial susceptibility testing by the clinical microbiology laboratory is important to confirm susceptibility to chosen empirical antimicrobial agents, or to detect resistance in individual bacterial isolates. Continue.. • Susceptibility testing of individual isolates is important with species that may possess resistance mechanisms (eg, members of the Enterobacteriaceae, Pseudomonas species, Staphylococcus species, Enterococcus species, and Streptococcus pneumoniae. In other hand susceptibility an important issue in 7/25/2017drug resistance surveillance Methods of susceptibility testing. • Phenotypic methods which is widely used in clinical microbiology methods. • Genotypic methods. It is only used for certain microorganisms for example defection of mecA in Staphylocococus aurues or detection of cetaingenes susc as coding ESBLs ,KPC and ... Molecular is difficult for standardized ant not applicable in many microbiology laboratories. This method is very expensive and needs special facilities and expertise staff. 7/25/2017 Phenotypic methods • Broth dilution tests: This method is used for detection of minimum inhibitory concentration (MIC) and is one of the earliest antimicrobial susceptibility testing methods was the macrobroth or tube-dilution method This procedure involved preparing two-fold dilutions of antibiotics (eg, 1, 2, 4, 8, and 16 µg/mL) in a liquid growth medium dispensed in test tubes.
    [Show full text]
  • Laboratory Diagnosis of Sexually Transmitted Infections, Including Human Immunodeficiency Virus
    Laboratory diagnosis of sexually transmitted infections, including human immunodeficiency virus human immunodeficiency including Laboratory transmitted infections, diagnosis of sexually Laboratory diagnosis of sexually transmitted infections, including human immunodeficiency virus Editor-in-Chief Magnus Unemo Editors Ronald Ballard, Catherine Ison, David Lewis, Francis Ndowa, Rosanna Peeling For more information, please contact: Department of Reproductive Health and Research World Health Organization Avenue Appia 20, CH-1211 Geneva 27, Switzerland ISBN 978 92 4 150584 0 Fax: +41 22 791 4171 E-mail: [email protected] www.who.int/reproductivehealth 7892419 505840 WHO_STI-HIV_lab_manual_cover_final_spread_revised.indd 1 02/07/2013 14:45 Laboratory diagnosis of sexually transmitted infections, including human immunodeficiency virus Editor-in-Chief Magnus Unemo Editors Ronald Ballard Catherine Ison David Lewis Francis Ndowa Rosanna Peeling WHO Library Cataloguing-in-Publication Data Laboratory diagnosis of sexually transmitted infections, including human immunodeficiency virus / edited by Magnus Unemo … [et al]. 1.Sexually transmitted diseases – diagnosis. 2.HIV infections – diagnosis. 3.Diagnostic techniques and procedures. 4.Laboratories. I.Unemo, Magnus. II.Ballard, Ronald. III.Ison, Catherine. IV.Lewis, David. V.Ndowa, Francis. VI.Peeling, Rosanna. VII.World Health Organization. ISBN 978 92 4 150584 0 (NLM classification: WC 503.1) © World Health Organization 2013 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO web site (www.who.int/about/licensing/copyright_form/en/index.html).
    [Show full text]
  • E-Test for Detection of Antimicrobial Susceptibility of Vancomycin (Glycopeptides) in Methicillin Resistant Staphylococcus Aureus (MRSA)
    IOSR Journal of Pharmacy and Biological Sciences (IOSR-JPBS) e-ISSN: 2278-3008, p-ISSN:2319-7676. Volume 7, Issue 3 (Jul. – Aug. 2013), PP 29-31 www.iosrjournals.org E-test for Detection of Antimicrobial susceptibility of Vancomycin (Glycopeptides) in Methicillin Resistant Staphylococcus aureus (MRSA) Flora Grace M (Ph.D.) Research Scholar Department of Zoology, Madras Christian College (Autonomous), Tambaram, Tamil Nadu, India, Abstract : E-test is a quantitative technique for determining the antimicrobial susceptibility of gram positive and gram negative bacteria. The system comprises a predefined antibiotic gradient which is used to determine the MIC (Minimum Inhibitory Concentration), in µg /ml of different antimicrobial agents against microorganisms as tested on agar media using overnight incubation. MIC of a given antibiotic in µg /ml that will inhibit the growth of a particular bacterium under defined experimental conditions. E-test directly quantifies antimicrobial susceptibility in terms of discrete MIC values. However in using a predefined stable and continuous antibiotic concentration gradient, E-test MIC values can be more precise and reproducible than results obtained from conventional procedures. E-test microbial concentration gradient is preformed, predefined and stable and is not dependent on diffusion. MIC of 0.5 µg /ml, 1 µg /ml and 1.5 µg/ml were observed when Vancomycin E-test was used to determine the glycopeptide susceptibility in MRSA (Methicillin Resistant Staphylococcus aureus). Keywords: Epsilometer, MIC, BSAC, AST, Susceptibility, MRSA, Vancomycin. I. Introduction The principle of the epsilometer test was first described in 1988 and was introduced commercially in 1991 by AB Biodisk. The Etest method (AB Biodisk, Solna, Sweden) gives an MIC result and is affected by test conditions in a similar way to other MIC and diffusion methods.
    [Show full text]
  • K052366 B. Purpo
    Page 1 of 9 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE A. 510(k) Number: K052366 B. Purpose for Submission: Addition of the antibiotic Tigecycline at concentrations of 0.016 - 256 µg/mL to the Etest® in the MIC range of 0.016 – 256 µg/mL with Gram positive and Gram negative aerobic bacteria, Streptococcus species other than S. pneumoniae, and anaerobic bacteria. C. Measurand: Tigecycline at 0.016 – 256 µg/mL D. Type of Test: Manual Antimicrobial Susceptibility Test System—growth based E. Applicant: AB BIODISK F. Proprietary and Established Names: Etest® Antimicrobial Susceptibility Test – Tigecycline at 0.016 – 256 µg/mL G. Regulatory Information: 1. Regulation section: 21 CFR 866.1640 – Antimicrobial susceptibility test powder 2. Classification: Class II 3. Product Code: JWY – Manual Antimicrobial Susceptibility Test Systems 4. Panel: 83 Microbiology H. Intended Use: 1. Intended use(s): Tigecycline at 0.016 – 256 µg/mL for in vitro diagnostic use for MIC determination with Gram positive and Gram negative aerobic bacteria, Streptococcus species other than S. pneumoniae, and anaerobic bacteria. Page 2 of 9 Etest® is a quantitative technique for the determination of antimicrobial susceptibility of both non-fastidious Gram negative and Gram positive aerobic bacteria, such as Enterobacteriaceae, Pseudomonas, Staphylococcus and Enterococcus species and fastidious bacteria, such as anaerobes, N. gonorrhoeae, S. pneumoniae, Streptococcus, and Haemophilus species. The system comprises a predefined antibiotic gradient which is used to determine the Minimum Inhibitory Concentration (MIC) in µg/mL of different antimicrobial agents against microorganisms as tested on agar media by overnight incubation. 2. Indication(s) for use: This submission is for the addition of antibiotic Tigecycline to the Etest® for MIC determination in the MIC range of 0.016 – 256 µg/mL with Gram positive and Gram negative aerobic bacteria, Streptococcus species other than S.
    [Show full text]
  • Adjunctive Use of Rifampin for the Treatment of Staphylococcus Aureus Infections: a Systematic Review of the Literature
    REVIEW ARTICLE Adjunctive Use of Rifampin for the Treatment of Staphylococcus aureus Infections A Systematic Review of the Literature Joshua Perlroth, MD; Melissa Kuo, MD; Jennifer Tan, MHS; Arnold S. Bayer, MD; Loren G. Miller, MD, MPH Background: Staphylococcus aureus causes severe life- efit of adjunctive rifampin use, particularly in osteomy- threatening infections and has become increasingly com- elitis and infected foreign body infection models; however, mon, particularly methicillin-resistant strains. Rif- many studies failed to show a benefit of adjunctive therapy. ampin is often used as adjunctive therapy to treat S aureus Few human studies have addressed the role of adjunc- infections, but there have been no systematic investiga- tive rifampin therapy. Adjunctive therapy seems most tions examining the usefulness of such an approach. promising for the treatment of osteomyelitis and pros- thetic device–related infections, although studies were Methods: A systematic review of the literature to iden- typically underpowered and benefits were not always seen. tify in vitro, animal, and human investigations that com- pared single antibiotics alone and in combination with Conclusions: In vitro results of interactions between rif- rifampin therapy against S aureus. ampin and other antibiotics are method dependent and often do not correlate with in vivo findings. Adjunctive Results: The methods of in vitro studies varied substan- rifampin use seems promising in the treatment of clini- tially among investigations. The effect of rifampin therapy cal hardware infections or osteomyelitis, but more de- was often inconsistent, it did not necessarily correlate with finitive data are lacking. Given the increasing incidence in vivo investigations, and findings seemed heavily de- of S aureus infections, further adequately powered in- pendent on the method used.
    [Show full text]